#BEGIN_DRUGCARD DB04639

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C15H15NO2

# Chemical_IUPAC_Name:
(2S)-2-amino-3-(4-phenylphenyl)propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2007-09-11 11:49:07 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Biphenylalanine

# HET_ID:
BIF

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C15H15NO2/c16-14(15(17)18)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9,14H,10,16H2,(H,17,18)/t14-/m0/s1

# InChI_Key:
InChIKey=JCZLABDVDPYLRZ-AWEZNQCLSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4639

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
241.2851

# Molecular_Weight_Mono:
241.110278729

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.1

# Predicted_LogS:
-3.6

# Predicted_Water_Solubility:
5.87e-02 g/l

# Primary_Accession_No:
DB04639

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
2761815

# PubChem_Substance_ID:
46505628

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@](N)(CC1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:32 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
TM:Virion

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
env

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Involved in structural molecule activity

# Drug_Target_1_General_References:
1404605	Li Y, Hui H, Burgess CJ, Price RW, Sharp PM, Hahn BH, Shaw GM: Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol. 1992 Nov;66(11):6587-600.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5727

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
95649

# Drug_Target_1_Name:
Envelope glycoprotein gp160

# Drug_Target_1_Number_of_Residues:
843

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00516	GP120
PF00517	GP41

# Drug_Target_1_Protein_Sequence:
>Envelope glycoprotein gp160
MRATEIRKNYQHLWKGGTLLLGMLMICSAAEQLWVTVYYGVPVWKEATTTLFCASDAKAY
DTEVHNVWATHACVPTDPNPQEVKLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVK
LTPLCVTLNCTDLRNATNTTSSSWETMEKGEIKNCSFNITTSIRDKVQKEYALFYNLDVV
PIDNASYRLISCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGTGPCTNVST
VQCTHGIRPVVSTQLLLNGSLAEEEIVIRSENFTNNAKTIIVQLNESVVINCTRPNNNTR
KSINIGPGRALYTTGEIIGDIRQAHCNLSKTQWENTLEQIAIKLKEQFGNNKTIIFNPSS
GGDPEIVTHSFNCGGEFFYCNSTQLFTWNDTRKLNNTGRNITLPCRIKQIINMWQEVGKA
MYAPPIRGQIRCSSNITGLLLTRDGGKDTNGTEIFRPGGGDMRDNWRSELYKYKVVKIEP
LGVAPTKAKRRVVQREKRAVGLGALFLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQN
NLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTTVPWNTS
WSNKSLNEIWDNMTWMKWEREIDNYTHIIYSLIEQSQNQQEKNEQELLALDKWASLWNWF
DITKWLWYIKIFIMIVGGLIGLRIVFVVLSIVNRVRQGYSPLSFQTHLPAQRGPDRPDGI
EEEGGERDRDRSGPLVDGFLAIIWVDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWGVL
KYWWNLLQYWIQELKNSAVSLLNATAIAVAEGTDRVIEILQRAFRAVLHIPVRIRQGLER
ALL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-31

# Drug_Target_1_Specific_Function:
Allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves

# Drug_Target_1_SwissProt_ID:
P35961

# Drug_Target_1_SwissProt_Name:
ENV_HV1Y2

# Drug_Target_1_Synonyms:
Env polyprotein
Envelope glycoprotein gp160 precursor

# Drug_Target_1_Theoretical_pI:
8.63

# Drug_Target_1_Transmembrane_Regions:
672-692

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
IGHG1

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
IGHG1

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1002129	Dreker L, Schwarz J, Reichel W, Hilschmann N: [Rule of antibody structure. the primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie), I: Purification and characterization of the protein, the L- and H-chains, the cyanogenbromide cleavage products, and the disulfide bridges (author's transl)] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1515-40.
4923144	Gall WE, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. X. Intrachain disulfide bonds. Biochemistry. 1970 Aug 4;9(16):3188-96.
5489771	Cunningham BA, Rutishauser U, Gall WE, Gottlieb PD, Waxdal MJ, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. VII. Amino acid sequence of heavy-chain cyanogen bromide fragments H1-H4. Biochemistry. 1970 Aug 4;9(16):3161-70.
5530842	Rutishauser U, Cunningham BA, Bennett C, Konigsberg WH, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. 8. Amino acid sequence of heavy-chain cyanogen bromide fragments H5-H7. Biochemistry. 1970 Aug 4;9(16):3171-81.
6287432	Ellison JW, Berson BJ, Hood LE: The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res. 1982 Jul 10;10(13):4071-9.
6884994	Schmidt WE, Jung HD, Palm W, Hilschmann N: [Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I] Hoppe Seylers Z Physiol Chem. 1983 Jun;364(6):713-47.
7236608	Deisenhofer J: Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981 Apr 28;20(9):2361-70.
826475	Ponstingl H, Hilschmann N: [The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1571-604.

# Drug_Target_2_HGNC_ID:
HGNC:5525

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4785

# Drug_Target_2_Locus:
14q32.33

# Drug_Target_2_Molecular_Weight:
36106

# Drug_Target_2_Name:
Ig gamma-1 chain C region

# Drug_Target_2_Number_of_Residues:
330

# Drug_Target_2_PDB_ID:
1HZH

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF07654	C1-set

# Drug_Target_2_Protein_Sequence:
>Ig gamma-1 chain C region
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P01857

# Drug_Target_2_SwissProt_Name:
IGHG1_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
8.31

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04639
